New shot could shield against malaria for months

NCT ID NCT06408857

Completed Prevention Sponsor: Gates Medical Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new drug called MAM01 to see if it is safe and could help prevent malaria for at least 4 months. It involved 125 healthy adults and children living in parts of Africa where malaria is common. Researchers gave different doses of MAM01 or a placebo and monitored for side effects and how the drug behaves in the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MAM01
What this could lead to: If successful, MAM01 could provide a new way to prevent malaria for several months, reducing infections in areas where malaria is common.
What could go wrong: This is an early Phase 1 trial focused on safety and dosing, so it is too soon to know if MAM01 will actually prevent malaria. The results may not apply to all populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Plasmodium falciparum malaria malaria prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY VOLUNTEERS

Contacts and locations

Locations

IDRC-Infectious Disease Research Collaboration, IDRC Tororo Hospital Station Road

Tororo, 749, Uganda
JCRC-Joint Clinical Research Centre

Kampala, 10005, Uganda

More trials for these conditions

Other studies related to the condition(s) this trial covers.